UNSPSC 51361928: Amobarbital sodium

This classification denotes a barbiturate with the molecular formula C11H17N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G0313KNC7D, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(3-methylbutyl)-, monosodium salt but more generally known as amobarbital sodium, which bears US NIH Compound Identifier 6149. European Medicines Agency schedules Amobarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00498MIG.

Most nations, for tariff and trade purposes, schedule amobarbital sodium under HS 29335300. As of Q4 2014, AMOBARBITAL SODIUM remains US FDA's Preferred Term for this commodity. Amobarbital sodium bears US NLM identifiers UMLS ID C0037479 and NCI Concept Code C76524. SMILES: CCC1(C(=O)NC(=O)[N-]C1=O)CCC(C)C.[NA+].

UNSPSC 51361928 Amobarbital sodium is a Commodity code that shows minimal recent alignment with state and local procurement activity. The three most recent opportunities posted under or near this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy programs (Texas HHS Commission), and generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations specifically target amobarbital sodium, a barbiturate controlled substance with narrow clinical use. The recent activity suggests the code may be misclassified or rarely used in state and local procurement, with actual pharmaceutical procurement occurring under broader family or segment-level codes that capture drug categories without specifying individual active pharmaceutical ingredients.

Issuing bodies using codes in this pharmaceutical space include state health and human services departments, county health authorities, and cooperative purchasing alliances spanning multiple states. The geographic spread covers Florida, Texas, Minnesota, and Oregon across the three recent opportunities. Seminole County posted IFB 60459723LAS on June 30, 2026, with a due date of July 26, 2023 (note: conflicting dates in source), seeking 1,900 units of naloxone annually with quarterly deliveries. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs. Minnesota's Department of Administration, administering MMCAP, released an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with contracts effective July 1, 2026. None of these solicitations reference amobarbital sodium, and the code itself shows no current state or local procurement activity of its own.